AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20456040 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine-L-aspartate (LOLA)
Number of subjects: 40
Study 20456040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 18201764 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifosine 100 mg daily or 900 mg weekly in combination with imatinib
Number of subjects: 5
Study 18201764 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids, topical antibiotics, and lubricating drops
Number of subjects: 5
Study 16377476 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial color Doppler flow imaging (TCDFI)
Number of subjects: 30
Study 16377476 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 30
Study 12554024 — intervention group
Group type: EXPERIMENTAL
Intervention: Squire's Quest! (intervention group)
Number of subjects: 1578
Study 12554024 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the program)
Number of subjects: 1578
Study 10874258 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enoxaparin (1 mg/kg) and unfractionated heparin (12,500 IU)
Number of subjects: 126
Study 10874258 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin (1 mg/kg) alone
Number of subjects: 126
Study 9416718 — intervention group
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope with in-line stabilization (ILS)
Number of subjects: 29
Study 9416718 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope without ILS
Number of subjects: 29
Study 9416718 — intervention group
Group type: EXPERIMENTAL
Intervention: Bullard laryngoscope with ILS
Number of subjects: 29
Study 9416718 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 29
Study 1587753 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic interstitial brachytherapy with iodine-125 implants
Number of subjects: 68
Study 3899199 — intervention group
Group type: EXPERIMENTAL
Intervention: fenfluramine
Number of subjects: 12
Study 3899199 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30255418 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg BID
Number of subjects: 39
Study 30255418 — intervention group
Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 39
Study 27266221 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-preferred route of delivery (vaginal delivery)
Number of subjects: 370
Study 27266221 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to perform cesarean delivery on maternal request (CDMR)
Number of subjects: 370
Study 24881993 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of nebivolol (20 mg/day) and valsartan (320 mg/day)
Number of subjects: 4161
Study 24881993 — intervention group
Group type: COMPARATOR
Intervention: Nebivolol (40 mg/day)
Number of subjects: 4161
Study 24881993 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (320 mg/day)
Number of subjects: 4161
Study 24881993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4161
Study 22619614 — intervention group
Group type: EXPERIMENTAL
Intervention: Project P.A.T.H.S. Tier 1 Program (experimental group)
Number of subjects: 5934
Study 22619614 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 5934
Study 20721488 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/kg body weight of oral praziquantel divided in two equal doses with 1 h interval (Group 1)
Number of subjects: 288
Study 20721488 — intervention group
Group type: COMPARATOR
Intervention: 50 mg/kg body weight of oral praziquantel (Group 2)
Number of subjects: 288
Study 18398278 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4 microg/kg
Number of subjects: 80
Study 18398278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 40 microg/kg
Number of subjects: 80
Study 16024518 — intervention group
Group type: COMPARATOR
Intervention: One set at slow speed
Number of subjects: 115
Study 16024518 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets at high speed
Number of subjects: 115
Study 16024518 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets at low speed
Number of subjects: 115
Study 16024518 — intervention group
Group type: EXPERIMENTAL
Intervention: One set at high speed
Number of subjects: 115
Study 12534505 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (3 injections of 5 U each, total 15 U)
Number of subjects: 10
Study 12534505 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (3 injections of 250 U each, total 750 U)
Number of subjects: 10
Study 10958578 — intervention group
Group type: EXPERIMENTAL
Intervention: Stressing the personal future consequences of tasks (extrinsic motivation)
Number of subjects: 310
Study 10958578 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 310
Study 8638792 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 0.1 mg/kg
Number of subjects: 80
Study 8638792 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 0.05 mg/kg
Number of subjects: 80
Study 8638792 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 0.2 mg/kg
Number of subjects: 80
Study 8638792 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 80
Study 8186137 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (250 mg/day)
Number of subjects: 366
Study 8186137 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole (100 mg/day)
Number of subjects: 366
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 25 mg/day
Number of subjects: 6
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 35 mg/day
Number of subjects: 6
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 45 mg/day
Number of subjects: 6
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin 55 mg/day
Number of subjects: 6
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (various dosages)
Number of subjects: 6
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (after discontinuation)
Number of subjects: 6
Study 2467488 — intervention group
Group type: EXPERIMENTAL
Intervention: Acitretin (dosages 45 or 55 mg/day)
Number of subjects: 6
Study 31149703 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study 31149703 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Number of subjects: 0
Study 31149703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31149703 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 0
Study 29072815 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg daily)
Number of subjects: 200
Study 29072815 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 200
Study 28805667 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of standardized ginger extract per day
Number of subjects: 51
Study 28805667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27989874 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetea teaTM (DT)
Number of subjects: 50
Study 27989874 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 50
Study 23336711 — intervention group
Group type: EXPERIMENTAL
Intervention: HYBRID (combined FTP and power training)
Number of subjects: 19
Study 23336711 — intervention group
Group type: COMPARATOR
Intervention: FTP (functional task practice)
Number of subjects: 19
Study 21047840 — intervention group
Group type: EXPERIMENTAL
Intervention: PRP injection
Number of subjects: 54
Study 21047840 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 54
Study 19880411 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic cardiomyopathy
Number of subjects: 133
Study 19880411 — intervention group
Group type: COMPARATOR
Intervention: Non-ischaemic cardiomyopathy
Number of subjects: 133
Study 17244103 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (Duragesic, 25 microg/h)
Number of subjects: 12
Study 17244103 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 12
Study 15492435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied three times a week for 12 weeks
Number of subjects: 34
Study 15492435 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34
Study 15492435 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream
Number of subjects: 34
Study 11505809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antibiotic and/or antiphlogistic regimen followed by L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A1/B1)
Number of subjects: 90
Study 11505809 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antibiotic and/or antiphlogistic regimen and L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A2/B2)
Number of subjects: 90
Study 11505809 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Carnitine 1 g x 2/day + acetyl-Carnitine 0.5 g x 2/day for 3 months (A3/B3)
Number of subjects: 90
Study 9561935 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment (i.t.)
Number of subjects: 64
Study 9561935 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 64
Study 10163331 — intervention group
Group type: COMPARATOR
Intervention: No treatment (untreated group)
Number of subjects: 50
Study 10163331 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy with antisecretory or cytoprotective drugs
Number of subjects: 50
Study 2792164 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 18
Study 2792164 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox combined with Cholestyramine
Number of subjects: 18
Study 2792164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 335771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine 25 mg
Number of subjects: 250
Study 335771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine 50 mg
Number of subjects: 250
Study 335771 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine 100 mg
Number of subjects: 250
Study 335771 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine 50 mg
Number of subjects: 250
Study 31802120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) 2-dose schedule
Number of subjects: 0
Study 31802120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) 3-dose schedule
Number of subjects: 0
Study 31802120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 2-dose schedule
Number of subjects: 0
Study 31802120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) 3-dose schedule
Number of subjects: 0
Study 31689771 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week supervised resistance exercise program combined with home-based aerobic exercise
Number of subjects: 60
Study 31689771 — intervention group
Group type: COMPARATOR
Intervention: Home-based aerobic exercise only
Number of subjects: 60
Study 28333997 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice (10 different games)
Number of subjects: 111
Study 28333997 — intervention group
Group type: COMPARATOR
Intervention: Repetitive practice (same exergame - ski slalom, twice weekly for 20 minutes over 5 weeks)
Number of subjects: 111
Study 23915078 — intervention group
Group type: EXPERIMENTAL
Intervention: Real scalpel debridement
Number of subjects: 80
Study 23915078 — intervention group
Group type: COMPARATOR
Intervention: Sham scalpel debridement
Number of subjects: 80
Study 19446806 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐SET
Number of subjects: 151
Study 19446806 — intervention group
Group type: COMPARATOR
Intervention: DET
Number of subjects: 151
Study 18923786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-motor-oral stimulation and non-nutritive sucking
Number of subjects: 98
Study 18923786 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation program
Number of subjects: 98
Study 16361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganirelix (0.25 mg/day)
Number of subjects: 203
Study 16361296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study 12566210 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition counseling version of TLC
Number of subjects: 190
Study 12566210 — intervention group
Group type: COMPARATOR
Intervention: Exercise version of TLC
Number of subjects: 190
Study 10999263 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated bouts of maximal voluntary isokinetic eccentric exercise (EX)
Number of subjects: 24
Study 10999263 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 24
Study 2401028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at 6 acupoints of Yang meridian, retained for 30 minutes, daily for 6 weeks.
Number of subjects: 63
Study 2401028 — intervention group
Group type: COMPARATOR
Intervention: Calan tablet 5 mg, administered 3 times a day for 6 weeks.
Number of subjects: 63
Study 7415382 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 0
Study 7415382 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 30819145 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational, individual and locally anchored exercise intervention (MILE) including four motivational interviews, six months' free membership to a local sports club, and a GPS-watch/activity monitor.
Number of subjects: 232
Study 30819145 — intervention group
Group type: COMPARATOR
Intervention: Routine care including one or two motivational interviews.
Number of subjects: 232
Study 30819145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (men)
Number of subjects: 232
Study 30819145 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (men)
Number of subjects: 232
Study 30819145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (women)
Number of subjects: 232
Study 30819145 — intervention group
Group type: COMPARATOR
Intervention: Routine care group (women)
Number of subjects: 232
Study 30819145 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-completers
Number of subjects: 232
Study 30819145 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers
Number of subjects: 232
Study 28163232 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature management at 33°C
Number of subjects: 939
Study 28163232 — intervention group
Group type: COMPARATOR
Intervention: Target temperature management at 36°C
Number of subjects: 939
Study 28163232 — intervention group
Group type: EXPERIMENTAL
Intervention: Myoclonic seizures
Number of subjects: 939
Study 28163232 — intervention group
Group type: EXPERIMENTAL
Intervention: Status myoclonus
Number of subjects: 939
Study 26992090 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 95
Study 26992090 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 95
Study 26992090 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin with supplemental insulin
Number of subjects: 95
Study 26992090 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Hr1-GTT >212 mg/dL)
Number of subjects: 95
Study 26992090 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (Wk1-mFG >95 mg/dL)
Number of subjects: 95
Study 24162381 — intervention group
Group type: EXPERIMENTAL
Intervention: iceMFP
Number of subjects: 521
Study 22353811 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and thalidomide
Number of subjects: 95
Study 22353811 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control)
Number of subjects: 95
Study 20637795 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief-based intervention (three, one hour in-school sessions facilitated by Cancer Council Queensland employees)
Number of subjects: 80
Study 20637795 — intervention group
Group type: COMPARATOR
Intervention: Control condition (students not receiving the intervention)
Number of subjects: 80
Study 17420344 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin (measured at days 3 to 5)
Number of subjects: 980
Study 17420344 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin
Number of subjects: 980
Study 17420344 — intervention group
Group type: EXPERIMENTAL
Intervention: NTproBNP
Number of subjects: 980
Study 17420344 — intervention group
Group type: EXPERIMENTAL
Intervention: Log copeptin
Number of subjects: 980
Study 17420344 — intervention group
Group type: EXPERIMENTAL
Intervention: Log NTproBNP
Number of subjects: 980
Study 17420344 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeptin above the median (approximately 7 pmol/L) in patients with NTproBNP above the median (approximately 900 pmol/L)
Number of subjects: 980
Study 16390748 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH‐A therapy
Number of subjects: 30
Study 16390748 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 12045509 — intervention group
Group type: COMPARATOR
Intervention: Back school
Number of subjects: 200
Study 12045509 — intervention group
Group type: COMPARATOR
Intervention: Joint manipulation
Number of subjects: 200
Study 12045509 — intervention group
Group type: COMPARATOR
Intervention: Myofascial therapy
Number of subjects: 200
Study 12045509 — intervention group
Group type: COMPARATOR
Intervention: Combined joint manipulation and myofascial therapy
Number of subjects: 200
Study 10825037 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A (6 mg/kg of body weight iv; maximum, 100 mg)
Number of subjects: 269
Study 10825037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study 8829888 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray
Number of subjects: 59
Study 8829888 — intervention group
Group type: COMPARATOR
Intervention: Oral ebastine
Number of subjects: 59
Study 8829888 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study 2704543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A ointment (all-trans retinoic acid)
Number of subjects: 11
Study 2704543 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 11
Study 7009819 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin (10 mg/kg/dose, 600 mg/dose maximum, twice daily for two days)
Number of subjects: 400
Study 7009819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 31063019 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recall protocol (phone invitation)
Number of subjects: 96
Study 31063019 — intervention group
Group type: COMPARATOR
Intervention: No active recall (no phone invitation)
Number of subjects: 96
Study 31063019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 96
Study 28536029 — intervention group
Group type: EXPERIMENTAL
Intervention: CIGB-247 vaccine with adjuvant VSSP, specific anti-VEGF IgG titer diminished but remained above pre-vaccination levels, gradual shift in anti-VEGF IgG response from IgG1 to IgG4, maintained antibodies able to interfere with VEGF/Receptor interaction, production of IFNγ secretion in CD8+ cells.
Number of subjects: 0
Study 26935748 — intervention group
Group type: EXPERIMENTAL
Intervention: 480 nm optical notch filter
Number of subjects: 48
Study 26935748 — intervention group
Group type: COMPARATOR
Intervention: 620 nm sham filter
Number of subjects: 48
Study 25492271 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + standard chelation
Number of subjects: 20
Study 25492271 — intervention group
Group type: COMPARATOR
Intervention: Standard chelation
Number of subjects: 20
Study 25492271 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine therapy
Number of subjects: 20
Study 22885164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab chemotherapy induction
Number of subjects: 460
Study 22885164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 460
Study 22885164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab chemotherapy induction and 2-year rituximab maintenance
Number of subjects: 460
Study 22885164 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab chemotherapy induction and maintenance
Number of subjects: 460
Study 20580146 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate lateral expansion technique
Number of subjects: 32
Study 20580146 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed lateral expansion technique
Number of subjects: 32
Study 20580146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 32
Study 18335394 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention for 3 months
Number of subjects: 130
Study 18335394 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological intervention with metformin or acarbose
Number of subjects: 130
Study 18335394 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 130
Study 16277712 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO 40,000 units once per week (group A)
Number of subjects: 148
Study 16277712 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous rHuEPO 40,000 units three times per week (group B)
Number of subjects: 148
Study 16277712 — intervention group
Group type: COMPARATOR
Intervention: Control group (intravenous iron saccharate alone)
Number of subjects: 148
Study 11798992 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision technique
Number of subjects: 20
Study 11798992 — intervention group
Group type: COMPARATOR
Intervention: Two-incision technique
Number of subjects: 20
Study 10730702 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshman seminar program (small classes with seminar leaders/mentors)
Number of subjects: 0
Study 10730702 — intervention group
Group type: COMPARATOR
Intervention: Control group (no freshman seminar experience)
Number of subjects: 0
Study 8646611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low workload condition (model available)
Number of subjects: 45
Study 8646611 — intervention group
Group type: COMPARATOR
Intervention: High workload condition (recall without aids)
Number of subjects: 45